Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Change City

The Securities and Exchange Commission today announced that Chyhe Becker has been named as an Associate Director in the Division of Economic and Risk Analysis (DERA). The appointment is effective immediately.

Dr. Becker assumes a new position in the division’s Office of Litigation Economics, created to reflect the significance of data-driven economic and statistical analysis in investigations and litigated cases. The office has almost tripled in size in the past three years, growing to a staff of 26 from nine, and has expanded to five regional offices in addition to the SEC’s Washington, D.C. headquarters.

“We are very fortunate to have someone with Chyhe’s talents and management expertise to lead our litigation economics efforts,” said DERA Director and SEC Chief Economist Mark J. Flannery. “This office provides valuable services to Enforcement and other SEC divisions, and Chyhe has built the group from the ground up. I cannot imagine a better person for this position.”

Dr. Becker said, “I am continually impressed by the depth of expertise and tireless dedication of DERA’s staff. It is an honor to work with this group of experts on behalf of the SEC and investors."

Dr. Becker has been the Assistant Director of the Office of Litigation Economics since 2009. She joined the SEC staff in 2008 as an Assistant Chief Economist in what was then known as the Office of Economic Analysis. Before that, she worked as an economist in the private sector for 11 years, including as a principal at Chicago Partners LLP and a principal at Deloitte Financial Advisory Services LLP. She holds a Ph.D. in financial economics and an MBA from the University of Chicago Booth School of Business and a B.A. from Yale University.

Source: SEC.gov

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.